(RTTNews.com) - Immunomedics Inc. (IMMU) presented results from two preclinical studies on the development of Dock-and-Lock or DNL derived novel therapeutic agents targeting solid tumors, including renal cell carcinomas or RCC.

RCC constitutes approximately 90% of kidney cancers. About one third of patients diagnosed with RCC have advanced or metastatic disease. These patients face a poor prognosis, because the cancer is resistant to conventional chemotherapy or radiotherapy. Resistance to therapy develops when cancer cells activate a communication system known as the insulin-like growth factor-I (IGF-I) to interact with their environment. Clinically, expression of IGF-I receptor (IGF-IR) in RCC is associated with poor long-term patient survival, particularly among patients with high-grade tumors.

The Company has previously developed hR1, a humanized anti-IGF-1R monoclonal antibody that binds to multiple tumor types, including RCC, resulting in moderate inhibition of cell growth. To enhance the anti-tumor activity of hR1, two novel multivalent/multifunctional agents, 1R-2b and Hex-hR1, were created using the Company's patented DNL conjugation technology. 1R-2b is composed of an intact hR1 antibody with 2 molecules of interferon-α2b (IFN-α2b) attached to it, whereas Hex-hR1 is comprised of 6 antigen-binding regions of hR1 tethered onto a common crystallizable region of the antibody.

For comments and feedback: contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

http://www.rttnews.com

...